Even though Advair’s main patent expired in 2010 and the patent on the Diskus inhaler expired in 2016, until now no-one has managed to get the FDA to approve a cheaper copy of the drug-device ...

Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...

and of concomitant disease or other drug therapy. In addition, as with other products containing beta 2-agonists, special caution should be observed when using Advair HFA in geriatric patients who ...

GlaxoSmithKline has confirmed it will face a challenging 2019 as generics of its big-selling Advair drug finally reach the US, as it continues the transformation of its business. The FDA approved ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is ... inhaled corticosteroid medication for a short period.

which have prevented key drug approvals so far. Looking ahead, Cipla aims to file its generic Advair product application from an alternative site by mid-FY 2025, which could gain approval towards ...